Clinical trials: Granzyme B PET/CT
Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent
[68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy
This diagnostic study investigates the value of 68Ga-NOTA-GZP PET imaging in predicting and evaluating immunotherapy response in malignant tumors by enrolling pathologically confirmed patients scheduled for immunotherapy and…
- Conditions
- Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, Colorectal Cancer Screening
- Trial name
- NCT06982053
- Testing
- Received 68Ga-NOTA-GZP PET scanning
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Myeloma
Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma
Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate…
- Trial name
- NCT03262389
- Testing
- Fludeoxyglucose PET CT, Sodium Acetate C11 PET CT, Fludeoxyglucose PET MRI
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Michael C Roarke, MD
Cancer
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell…
- Trial name
- NCT07724535
- Testing
- 18F-grazy-02
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peking University Cancer Hospital & Institute
T-NK Cell Lymphoma
The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.
- Trial name
- NCT06863441
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Esophageal Cancer
A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer
The purpose of this study is to evaluate the investigators ability to obtain reliable and meaningful 11C-Choline PET-CT images of esophageal cancer.
- Trial name
- NCT01051479
- Testing
- C11-Choline
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Wake Forest University Health Sciences
Solid Tumor Malignancies, Hematologic Cancer
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
- Conditions
- Solid Tumor Malignancies, Hematologic Cancer, Lung Cancer, Esophagus Cancer
- Trial name
- NCT07039474
- Testing
- 18F-G1
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Prostate Cancer
PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
Imaging and staging of prostate cancer is critical for surgical and treatment planning. In this protocol we will image patients with suspected metastatic prostate cancer using 11C-Choline PET and Gallium-68 labeled HBED-CC PSMA…
- Trial name
- NCT03768349
- Testing
- Ga-68 PSMA11, F-18 PSMA 1007
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Mayo Clinic
Prostate Cancer
C11 Sodium Acetate PET/CT Imaging of PCa
The investigators propose to conduct Carbon-11 Sodium Acetate PET/CT studies. The purpose of our study is to evaluate the impact of Carbon-11 Sodium Acetate PET/CT studies on patient management in patients with prostate cancer.
- Trial name
- NCT02826395
- Testing
- Carbon-11 Sodium Acetate
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Multiple Myeloma
C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT
Positron emission tomography combined with computed tomography using carbon-11 acetate (ACT PET/CT) may help detect lesions before treatment and evaluate response following therapy in patients with from multiple myeloma (MM).
- Trial name
- ACTMM (NCT01691300)
- Testing
- ACT PET/CT
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Chang Gung Memorial Hospital
Prostate Cancer
C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer
RATIONALE: New diagnostic procedures, such as C-11 choline PET-CT scan, may be effective in finding cancer that has spread to the bone and lymph nodes in patients with prostate cancer.
- Trial name
- NCT00804245
- Testing
- needle biopsy, PET-CT scans supplemented with 11C-Choline tracer
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
PET/CT, Solid Tumors, Adult
Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy
Malignant solid tumors, characterized by their persistently high incidence and mortality rates, pose a significant threat to human health and life, imposing a substantial societal burden.
- Conditions
- PET/CT, Solid Tumors, Adult, Solid Tumors, Advanced Solid Tumors
- Trial name
- GZMB_PET (NCT06916442)
- Testing
- PET/CT Imaging with GZMB-targeted tracer
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhongnan Hospital
Soft Tissue Sarcomas, Thyroid Cancer
11C-Acetate PET/CT Non-FDG-Avid Tumors
F18-FDG is the widely used PET tracer in the routine practice of oncologic disease imaging using the technology of PET-CT. However, FDG-avidity is a characteristic of the individual tumor.
- Conditions
- Soft Tissue Sarcomas, Thyroid Cancer, Lung Cancer, Indolent Lymphoma
- Trial name
- NCT00687778
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Cancer
68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-grazytracer in subjects with solid tumor or lymphoma receiving immunotherapy.
- Trial name
- NCT05000372
- Testing
- 68Ga-grazytracer
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Peking University Cancer Hospital & Institute
Breast Cancer Invasive
GzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer
To explore the efficacy of 68Ga-GZMB PET/CT in assessing the response to neoadjuvant therapy for breast cancer, and to investigate the optimal SUVmax threshold of 68Ga-GZMB PET/CT for predicting pathological complete response…
- Trial name
- GzmB-PET4BC (NCT06725940)
- Testing
- 68Ga-GZMB PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Diffuse Large B-Cell Lymphoma
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.
- Trial name
- NCT06755775
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Ruijin Hospital
Hyperparathyroidism
Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma
The purpose of the study is to determine a possible input of C11-Choline PET/CT in identification and localization of a parathyroid adenoma (PTA).
- Trial name
- NCT01221896
- Testing
- C11-Choline PET/CT
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Hadassah Medical Organization
Triple Negative Breast Cancer, Immune Checkpoint Inhibitor
Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
This study plans to enroll 30 patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who are scheduled to receive at least two cycles of a regimen containing an immune checkpoint inhibitor (ICI).
- Conditions
- Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT
- Trial name
- NCT07705438
- Testing
- [68Ga]Ga-DOTA-GSI PET/CT (Granzyme B PET/CT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Prostate Cancer
Comparing PET-CT Using C-11 Choline and 18F-Fluoromethylcholine in Patients With Metastatic Prostate Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) and computed tomography (CT) imaging, may help find and diagnose metastatic prostate cancer.
- Trial name
- NCT01132599
- Testing
- C-11 choline, 18F-fluoromethylcholine
- Where
- United Kingdom
- Sponsor
- Cancer Research UK
Lung Cancer, Pancreatic Cancer
C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR).
The EGFR is one of the most frequently overexpressed proteins in various cancers including lung cancer, and is related to tumor progression and resistance to most treatments.
- Trial name
- EGFR; PET/CT (NCT01717807)
- Testing
- C11-Erlotinib PET/CT
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Hadassah Medical Organization
Gliomas
C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
This study will investigate how well Carbon Acetate PET/CT imaging helps to correctly identify recurrent tumor versus post treatment effects (radionecrosis) in patients with previously treated high grade brain gliomas.
- Trial name
- NCT01961934
- Testing
- Sodium Acetate C11 PET/CT Imaging
- Where
- United States
- Sponsor
- Phoenix Molecular Imaging